Honeywell has announced the expansion of its Spectra Medical Grade (MG) Bio fiber portfolio with a blue-hued fibre that provides a strong visual aid to better differentiate between multiple suture sets in more complex surgeries. By creating clear colour contrast, the new fibre enables healthcare professionals to operate more accurately and efficiently, promoting greater safety and comfort for patients. 

Engineered to be both ultra-lightweight and ultra-high-strength, Honeywell’s Spectra MG Bio fibre provides superior resistance to chemicals, fatigue and abrasion when compared to conventional polyethene fibre, making it an optimal solution for minimally invasive surgeries. Earlier this year, the technology received ISO 13485 certification.

The addition of a coloured variety to the Spectra MG Bio portfolio means the biomaterial can be utilised and trusted by a wide range of manufacturers building increasingly smaller, stronger and lighter devices. For the orthopaedic market, coloured Spectra MG Bio fibre provides new advantages for both existing devices and emerging trends used in corrective surgeries, such as robotics that reduce procedure durations and smart implants that flag dangerous bacterial presence. The advancement will help to support the growing worldwide market for orthopaedic devices, which is expected to reach a $43.1 billion value by 2024. 

Honeywell’s new coloured Spectra MG Bio fibre is expected to be commercially available globally in Q3 2022, making the technology accessible to thriving orthopaedic device markets in regions including the US, EU, India, Asia Pacific and Latin America.